Abstracts

A Proposed HIV Reference Sample Characterized by Three Next-Generation Sequencing Platforms

Background: “Deep” sequencing allows detection of low frequency minority variants, but establishing the analytical characteristics of such assays, including the error rate and limit of detection, will require repeated sequencing of known reference samples. We present sequencing results from three next-generation platforms for one such potential sample. Methodology: Fifteen infectious viral clones, each containing a…

Pan Degenerate Amplification and Adaptation for Highly Sensitive Detection of ARV Drug Resistance

Background: Current drug resistance detection assays are unable to rapidly detect low-level, clinically relevant variants. Molecular probes, such as TaqMan-MGB, can distinguish a single nucleotide polymorphism (SNP) of interest but with the caveat that probes are sensitive to secondary polymorphisms (i.e. non-drug resistance) in the probe-binding region. The highly polymorphic nature of HIV results in…

Tropism Testing by MiSeq Is Comparable to 454-Based Methods but Exhibits Contamination Issues

Background: Bench-top next-generation sequencing (NGS) has become increasingly popular for HIV applications within the past five years. While “454”-based methods have dominated HIV research, the Illumina MiSeq is gaining popularity based on cost, ease of use, read depth and accuracy through homopolymer regions. Methodology: A total of 514 plasma samples were run on two NGS…

Impaired IL-23 signalling and Th17 dysfunction in HIV infection

Background: Th17 cells maintain gut homeostasis by co-ordinating a variety of innate and adaptive immune responses. HIV infection causes a profound depletion of gut Th17 cells, contributing to loss of mucosal barrier function and microbial translocation, thus driving systemic immune activation. Despite normalization of circulating CD4+ T cell counts with highly active antiretroviral therapy (HAART),…

Th17 and Tregs at Early HIV Infection Influence Disease Progression and HIV Specific CD8+ Responses

Background: Th17 and Treg subsets have been related to HIV/SIV disease progression. Their role and direct relation with specific HIV-adaptive T cell responses during primary HIV infection (PHI) are unexplored topics. Aim: To analyze the frequency and balance of Th17 and Treg subsets and the correlation with clinical parameters immune activation and HIV-specific responses during…

Profound Lung CD4+ T-Cell Depletion in HIV-Associated Chronic Obstructive Pulmonary Disease

Background: As overall survival improves, individuals with chronic HIV infection become susceptible to other chronic diseases. In this regard, select HIV-infected individuals develop accelerated chronic obstructive pulmonary disease (COPD). We hypothesized patients with HIV-associated COPD develop dysregulation of lung mucosal immunity compared to HIV-infected individuals without COPD. Methodology: To test our hypothesis, we evaluated the…

Severe depletion of lung CD4 T cells during HIV infection impairs alveolar macrophage function

Background: HIV establishes a widespread reservoir of infected cells, particularly within mucosal tissues, which house over 90% of the body’s lymphocytes. In the lung HIV infects resident CD4+ T cells and macrophages, leading to virus-specific local responses. In 70% of all HIV patients this results in lung complications and increased susceptibility towards deadly diseases such…

Site Specific HIV-Infection of Th17 Cells in the Human Female Reproductive Tract

Background: Successful prevention of sexual transmission of HIV in women requires a substantial increase in our knowledge regarding HIV-target cell availability and regulation in the female reproductive tract (FRT). In this study we analyzed CD4+ T cell phenotype and susceptibility to HIV-infection in three different FRT compartments likely involved in HIV-acquisition: endometrium (EM), endocervix (CX)…

Atazanavir/Cobicistat Fixed-Dose Combination Is Bioequivalent to the Separate Agents

Background: The once-daily protease inhibitor atazanavir (ATV) boosted with low-dose ritonavir (RTV) and combined with other antiretrovirals is approved for the treatment of HIV-1 infection. Cobicistat (COBI), an alternative booster with more selective CYP3A inhibition but no antiretroviral activity or CYP induction, has similar pharmacoenhancing activity as RTV. A Phase III trial has demonstrated comparable…